Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Pracinostat in Myelofibrosis
NCT02267278Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pracinostat in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 3 months. Started Jan 2015; status: completed.
02
Drugs
pracinostat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02267278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267278.